SEARCH

SEARCH BY CITATION

References

  • 1
    Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 37890.
  • 2
    Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 2534.
  • 3
    Kudo M, Han KH, Kukudo N et al. Liver Cancer Working Group report. Jpn. J. Clin. Oncol. 2010; 40 (Suppl. 1): i1927.
  • 4
    Lee JM, Han KH. Positioning and indication of sorafenib in the treatment algorithm and real practical setting: western and eastern approach—Asian perspective. Oncology 2010; 78 (Suppl. 1): 16771.
  • 5
    Kim R, Byrne MT, Tan A et al. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology 2011; 25: 28391.
  • 6
    Kim HY, Park J-W, Nam B-H et al. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatment. J. Gastroenterol. Hepatol. 2011; 26: 16128.
  • 7
    Han K-H, Seong J, Kim JK et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 9951003.
  • 8
    Sangro B, Carpanese L, Cianni R et al. Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology 2011; 54: 86878. [Epub ahead of print].
  • 9
    Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 58895.
  • 10
    Park JY, Ahn SH, Yoon YJ et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 12937.
  • 11
    Lee S, Yoon SH, Park JY et al. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest. New Drugs [Epub ahead of print].
  • 12
    Qin S, Bai Y, Ye S et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J. Clin. Oncol. 2010; 28: 15s. (suppl; abstr 4008).